Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful ...
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct 23, 2026-- Takeda ( TSE:4502/NYSE:TAK ) announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients …